➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Mallinckrodt
Merck
McKesson
Medtronic

Last Updated: August 4, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TYBOST

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for TYBOST

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02503462 ↗ Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals Recruiting University Hospital, Basel, Switzerland Phase 4 2015-07-01 The purpose of this study is to assess whether a boosting by cobicistat results in similar concentrations of darunavir in the brain compared to a boosting by ritonavir.
NCT02565888 ↗ A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat Completed Radboud University Phase 1 2015-11-01 This study aims to provide the evidence that 150mg of cobicistat will have the same effect on the pharmacokinetics of daclatasvir 30mg QD as 100mg of ritonavir, when given together with atazanavir 300mg.
NCT03858491 ↗ Pharmacokinetic Boosting of Osimertinib Not yet recruiting The Netherlands Cancer Institute Early Phase 1 2019-03-01 The main objective of this study is to evaluate if systemic exposure of osimertinib (i.e. AUC) is increased when osimertinib is co-administered with cobicistat in patients with relatively low plasma trough concentration while receiving the standard osimertinib dose.
NCT03858491 ↗ Pharmacokinetic Boosting of Osimertinib Not yet recruiting ZonMw: The Netherlands Organisation for Health Research and Development Early Phase 1 2019-03-01 The main objective of this study is to evaluate if systemic exposure of osimertinib (i.e. AUC) is increased when osimertinib is co-administered with cobicistat in patients with relatively low plasma trough concentration while receiving the standard osimertinib dose.
NCT03858491 ↗ Pharmacokinetic Boosting of Osimertinib Not yet recruiting Academisch Ziekenhuis Maastricht Early Phase 1 2019-03-01 The main objective of this study is to evaluate if systemic exposure of osimertinib (i.e. AUC) is increased when osimertinib is co-administered with cobicistat in patients with relatively low plasma trough concentration while receiving the standard osimertinib dose.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for TYBOST

Condition Name

Condition Name for TYBOST
Intervention Trials
Non Small Cell Lung Cancer 1
HIV 1
Hepatitis C 1
AIDS-related Dementia Complex 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for TYBOST
Intervention Trials
Carcinoma, Non-Small-Cell Lung 1
Hepatitis C 1
Hepatitis 1
Dementia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TYBOST

Trials by Country

Trials by Country for TYBOST
Location Trials
Netherlands 1
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TYBOST

Clinical Trial Phase

Clinical Trial Phase for TYBOST
Clinical Trial Phase Trials
Phase 4 1
Phase 1 1
Early Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for TYBOST
Clinical Trial Phase Trials
Not yet recruiting 1
Recruiting 1
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TYBOST

Sponsor Name

Sponsor Name for TYBOST
Sponsor Trials
Academisch Ziekenhuis Maastricht 1
ZonMw: The Netherlands Organisation for Health Research and Development 1
The Netherlands Cancer Institute 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for TYBOST
Sponsor Trials
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Dow
Express Scripts
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.